Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for prevention of acute graft-versus-host disease after HLA-matched allogeneic hematopoietic progenitor cell transplantation
ACTRN12612000726853Phase 2Recruiting
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Royal Brisbane and Women's Hospital. Primary endpoint: Incidence of grade II-IV acute graft-versus-host disease. Started Jan 2012; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ACTRN12612000726853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000726853.